CA2382065A1 - Bioavailable dosage form of isotretinoin - Google Patents
Bioavailable dosage form of isotretinoin Download PDFInfo
- Publication number
- CA2382065A1 CA2382065A1 CA002382065A CA2382065A CA2382065A1 CA 2382065 A1 CA2382065 A1 CA 2382065A1 CA 002382065 A CA002382065 A CA 002382065A CA 2382065 A CA2382065 A CA 2382065A CA 2382065 A1 CA2382065 A1 CA 2382065A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- formulation
- less
- oil
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005280 isotretinoin Drugs 0.000 title claims abstract description 35
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 title claims abstract description 34
- 239000002552 dosage form Substances 0.000 title claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims description 36
- 238000009472 formulation Methods 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 17
- 239000000375 suspending agent Substances 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 244000068988 Glycine max Species 0.000 claims description 9
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229940045860 white wax Drugs 0.000 claims description 4
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 3
- 239000007963 capsule composition Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- 239000008159 sesame oil Substances 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 9
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 2
- 238000007796 conventional method Methods 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-HWCYFHEPSA-N 13-cis-retinol Chemical compound OC/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-HWCYFHEPSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN596/DEL/00 | 2000-06-16 | ||
| IN596DE2000 IN192188B (enExample) | 2000-06-16 | 2000-06-16 | |
| PCT/IB2001/000581 WO2001095886A1 (en) | 2000-06-16 | 2001-04-09 | Bioavailable dosage form of isotretinoin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2382065A1 true CA2382065A1 (en) | 2001-12-20 |
Family
ID=11097063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002382065A Abandoned CA2382065A1 (en) | 2000-06-16 | 2001-04-09 | Bioavailable dosage form of isotretinoin |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6740337B2 (enExample) |
| EP (1) | EP1294357A1 (enExample) |
| JP (1) | JP2004503493A (enExample) |
| CN (1) | CN1196475C (enExample) |
| AP (1) | AP2002002423A0 (enExample) |
| AU (1) | AU782094B2 (enExample) |
| BG (1) | BG106414A (enExample) |
| BR (1) | BR0106752A (enExample) |
| CA (1) | CA2382065A1 (enExample) |
| CZ (1) | CZ2002694A3 (enExample) |
| EA (1) | EA004808B1 (enExample) |
| EE (1) | EE200200074A (enExample) |
| HK (1) | HK1052302A1 (enExample) |
| HR (1) | HRP20020148A2 (enExample) |
| HU (1) | HUP0203717A3 (enExample) |
| IL (1) | IL148176A0 (enExample) |
| IN (1) | IN192188B (enExample) |
| MX (1) | MXPA02001669A (enExample) |
| NZ (1) | NZ517142A (enExample) |
| OA (1) | OA12008A (enExample) |
| PL (1) | PL352838A1 (enExample) |
| SK (1) | SK2252002A3 (enExample) |
| UA (1) | UA74793C2 (enExample) |
| WO (1) | WO2001095886A1 (enExample) |
| ZA (1) | ZA200201240B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2225600T3 (es) * | 2000-09-22 | 2005-03-16 | Galephar M/F | Composicion semi-solida de isotretinoina. |
| EP1527774A1 (en) | 2003-11-03 | 2005-05-04 | Basilea Pharmaceutica AG | New formulation for retinoid-containing soft gelatin capsules |
| US20070099996A1 (en) * | 2003-05-20 | 2007-05-03 | Shashikanth Isloor | Pharmaceutical compositions of acitretin |
| US20070254858A1 (en) * | 2006-04-27 | 2007-11-01 | Cronk Peter J | Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects |
| US20070254025A1 (en) * | 2006-04-27 | 2007-11-01 | Cronk Peter J | Oral contraceptive and acne medication combination and treatment of acne with reduced side effects |
| RU2322998C1 (ru) * | 2006-11-16 | 2008-04-27 | Общество с ограниченной ответственностью "Березовый мир" | Носитель лекарственных и диагностических средств |
| KR101434706B1 (ko) * | 2007-02-16 | 2014-08-26 | 아스카 세이야쿠 가부시키가이샤 | 미립자 유성 현탁액을 포함하는 의약 조성물 |
| WO2008102375A2 (en) * | 2007-02-20 | 2008-08-28 | Ipca Laboratories Limited | A process for preparation of highly pure isotretinoin |
| US9078925B2 (en) | 2012-06-18 | 2015-07-14 | Galephar Pharmaceutical Research, Inc. | Pharmaceutical semi-solid composition of isotretinoin |
| CA2987177A1 (en) * | 2015-05-25 | 2016-12-01 | Sun Pharmaceutical Industries Limited | Once-daily oral pharmaceutical composition of isotretinoin |
| US10517846B2 (en) | 2016-05-26 | 2019-12-31 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for treating acne |
| KR20250054055A (ko) * | 2022-07-01 | 2025-04-22 | 아크로테크 바이오파마 인코포레이티드. | 이소트레티노인을 포함하는 제약 조성물 및 그의 제조 방법 및 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4016254A (en) * | 1972-05-19 | 1977-04-05 | Beecham Group Limited | Pharmaceutical formulations |
| CA1282326C (en) * | 1984-12-14 | 1991-04-02 | Paul J. Jarosz | Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient |
| US4808630A (en) | 1987-01-16 | 1989-02-28 | United States Of America | Method of treating psychotic illnesses |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| PE20001227A1 (es) * | 1998-10-30 | 2000-11-06 | Hoffmann La Roche | Procesos para producir una composicion de isotretinoina |
| US6284283B1 (en) * | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
-
2000
- 2000-06-16 IN IN596DE2000 patent/IN192188B/en unknown
-
2001
- 2001-04-09 PL PL01352838A patent/PL352838A1/xx not_active Application Discontinuation
- 2001-04-09 CN CNB018024173A patent/CN1196475C/zh not_active Expired - Fee Related
- 2001-04-09 US US09/829,246 patent/US6740337B2/en not_active Expired - Fee Related
- 2001-04-09 OA OA1200200055A patent/OA12008A/fr unknown
- 2001-04-09 WO PCT/IB2001/000581 patent/WO2001095886A1/en not_active Ceased
- 2001-04-09 EP EP01917381A patent/EP1294357A1/en not_active Withdrawn
- 2001-04-09 AP APAP/P/2002/002423A patent/AP2002002423A0/en unknown
- 2001-04-09 SK SK225-2002A patent/SK2252002A3/sk unknown
- 2001-04-09 EE EEP200200074A patent/EE200200074A/xx unknown
- 2001-04-09 IL IL14817601A patent/IL148176A0/xx unknown
- 2001-04-09 AU AU44459/01A patent/AU782094B2/en not_active Ceased
- 2001-04-09 MX MXPA02001669A patent/MXPA02001669A/es active IP Right Grant
- 2001-04-09 CZ CZ2002694A patent/CZ2002694A3/cs unknown
- 2001-04-09 BR BR0106752-4A patent/BR0106752A/pt not_active IP Right Cessation
- 2001-04-09 HU HU0203717A patent/HUP0203717A3/hu unknown
- 2001-04-09 HR HR20020148A patent/HRP20020148A2/hr not_active Application Discontinuation
- 2001-04-09 EA EA200200166A patent/EA004808B1/ru not_active IP Right Cessation
- 2001-04-09 JP JP2002510065A patent/JP2004503493A/ja active Pending
- 2001-04-09 NZ NZ517142A patent/NZ517142A/en unknown
- 2001-04-09 CA CA002382065A patent/CA2382065A1/en not_active Abandoned
- 2001-04-09 HK HK03104641.2A patent/HK1052302A1/zh unknown
- 2001-09-04 UA UA2002031946A patent/UA74793C2/uk unknown
-
2002
- 2002-02-13 ZA ZA200201240A patent/ZA200201240B/en unknown
- 2002-02-14 BG BG06414A patent/BG106414A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA004808B1 (ru) | 2004-08-26 |
| HRP20020148A2 (en) | 2003-12-31 |
| SK2252002A3 (en) | 2002-08-06 |
| HK1052302A1 (zh) | 2003-09-11 |
| WO2001095886A1 (en) | 2001-12-20 |
| EE200200074A (et) | 2003-04-15 |
| US20020025338A1 (en) | 2002-02-28 |
| ZA200201240B (en) | 2002-09-02 |
| IL148176A0 (en) | 2002-09-12 |
| UA74793C2 (en) | 2006-02-15 |
| BR0106752A (pt) | 2002-04-16 |
| MXPA02001669A (es) | 2002-08-06 |
| CN1196475C (zh) | 2005-04-13 |
| CN1388757A (zh) | 2003-01-01 |
| OA12008A (en) | 2006-04-19 |
| AU4445901A (en) | 2001-12-24 |
| CZ2002694A3 (cs) | 2002-08-14 |
| AP2002002423A0 (en) | 2002-03-31 |
| EA200200166A1 (ru) | 2002-10-31 |
| US6740337B2 (en) | 2004-05-25 |
| HUP0203717A3 (en) | 2003-05-28 |
| HUP0203717A2 (hu) | 2003-04-28 |
| IN192188B (enExample) | 2004-03-13 |
| AU782094B2 (en) | 2005-06-30 |
| PL352838A1 (en) | 2003-09-08 |
| JP2004503493A (ja) | 2004-02-05 |
| NZ517142A (en) | 2003-08-29 |
| EP1294357A1 (en) | 2003-03-26 |
| BG106414A (en) | 2002-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0184942B1 (en) | Improved pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient | |
| CA2690488C (en) | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof | |
| US20030232097A1 (en) | Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen | |
| JPH07116021B2 (ja) | 医薬品のカプセル化の簡易化 | |
| KR20060066665A (ko) | 연질캡슐제 | |
| US6740337B2 (en) | Bioavailable dosage form of isotretinoin | |
| AU748396B2 (en) | Composition | |
| JPS6230965B2 (enExample) | ||
| EP3397248A1 (en) | Pharmaceutical composition comprising dutasteride and propylene glycol monolaurate and preparation method of the same | |
| EP1455730A1 (en) | Isotretinoin nanoparticulate compositions | |
| CN116350598A (zh) | 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法 | |
| US20040146537A1 (en) | Oily wax matrix suspension formulation comprising pharmacologically active agents | |
| CN118304270B (zh) | 一种维生素d滴剂及其制备方法 | |
| AU2002240206B2 (en) | Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle | |
| AU2002240206A1 (en) | Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle | |
| CN118304279A (zh) | 一种骨化三醇自微乳口溶膜及其制备方法 | |
| BG62234B1 (bg) | Фармацевтични състави,съдържащи гемфиброзил | |
| CA2303443A1 (en) | Compositions adapted for prolonged residence in the nasal pharynx |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |